ArticleClinical kidney journal2018
Sevelamer reduces endothelial inflammatory response to advanced glycation end products.
Article in Clinical kidney journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- In vitro anti-inflammatory effects of vitamin D supplementation may be blurred in hemodialysis patients.Clinics (Sao Paulo, Brazil) · 2021Trial
- Long-Term Intensive Lifestyle Intervention Promotes Improvement of Stage III Diabetic Nephropathy.Medical science monitor : international medical journal of experimental and clinical research · 2019Trial
- Targeting Uremic Toxins in Chronic Kidney Disease: Current Challenges and Emerging Therapeutic Strategies.Toxins · 2026Review
- Functional Molecular Plasma Biomarkers of Inflammation and Repair in Kidney Disease Progression in Gum Arabica Modality of CKD.International journal of molecular sciences · 2026Article
- Dyslipidemia in Peritoneal Dialysis: Implications for Peritoneal Membrane Function and Patient Outcomes.Biomedicines · 2024Review
- The nonlinear relationship between estimated glomerular filtration rate and cardiovascular disease in US adults: a cross-sectional study from NHANES 2007-2018.Frontiers in cardiovascular medicine · 2024Article
- Article
- Contribution of RAGE axis activation to the association between metabolic syndrome and cancer.Molecular and cellular biochemistry · 2021Review
- Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia.International journal of nephrology and renovascular disease · 2021Review
- Uremic Toxins: An Alarming Danger Concerning the Cardiovascular System.Frontiers in physiology · 2021Review
- Most exposed: the endothelium in chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020Review
- How do Uremic Toxins Affect the Endothelium?Toxins · 2020Review
- Phosphate Binders and Nonphosphate Effects in the Gastrointestinal Tract.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2020Review
- Strategies for Phosphate Control in Patients With CKD.Kidney international reports · 2019Review
- Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2019Review
- The newClinical kidney journal · 2019Article
- ApoA-I Mimetic Peptide Reduces Vascular and White Matter Damage After Stroke in Type-2 Diabetic Mice.Frontiers in neuroscience · 2019Article
- Uremia Impacts VE-Cadherin and ZO-1 Expression in Human Endothelial Cell-to-Cell Junctions.Toxins · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvanced glycation end products (AGEs) have been related to the pathogenesis of cardiovascular diseases (CVD), chronic kidney disease (CKD) and diabetes mellitus. We sought to investigate the binding capacity of sevelamer to both AGEs and uremic serum
methodsAGEs were prepared by albumin glycation and characterized by absorbance and electrophoresis. Human endothelial cells were incubated in culture media containing AGEs and uremic serum with or without sevelamer. Receptor for advanced glycation end product (RAGE) expression was evaluated through immunocytochemistry and western blot to explore the interactions between AGEs and the endothelium. Inflammatory and endothelial dysfunction biomarkers, such as interleukin 6 (IL-6) and IL-8, monocyte chemoattractant protein-1 (MCP-1), plasminogen activator inhibitor-1 (PAI-1) and serum amyloid A (SAA) were also measured in cell supernatant. The chemotactic property of the supernatant was evaluated.
resultsAGEs significantly induced the expression of RAGE, inflammatory and endothelial activation biomarkers [IL-6, (P
conclusionsSevelamer decreased both endothelial expression of RAGE and endothelial dysfunction biomarkers, induced by AGEs, and uremic serum. Further studies are necessary for a better understanding of the potential protective role of sevelamer on uremic serum and AGEs-mediated endothelial dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.